London-based GlamorousAI secures £440k grant funding from Innovate UK
- 8 April 2021
London-based GlamorousAI Secures Grant From Innovate UK to Fund a $500k Project toward Development of New Treatments For Glioblastoma Multiforme. GlamorousAI, a leading artificial intelligence biotech company pioneering innovation in small data drug discovery, and King’s College London enter into a collaboration to unlock new drug development opportunities for Glioblastoma Multiforme. The company announced today funding from Innovate UK to apply its AI-first platform, Rosalind, to the discovery of novel therapeutic targets, biomarkers and leads for Glioblastoma Multiforme. Glioblastoma Multiforme is the most common and aggressive brain tumour in adults affecting more than 100,000 people annually. Despite multimodal therapy, the
read moreOxbotica secures £34.45 million Series B investment led by bp
- 6 January 2021
OXBOTICA RAISES $47 MILLION TO DEPLOY AUTONOMY SOFTWARE PLATFORM AROUND THE WORLD Oxbotica raises $47 million cementing its position as a global leader in autonomous vehicle softwareInvestment raised from across the globe including Australia, China, UK, and the USA with bp ventures a lead investorOxbotica demonstrates the commercial viability of its universal autonomy software platform, deploying in industries today London, UK, Wednesday 6th January 2021: Oxbotica, a global leader in autonomous vehicle software, has announced the completion of a $47 million Series B investment with partners across the globe led by bp ventures. The funding will accelerate Oxbotica’s commercial deployment of
read moreExscientia secures £21.54 million Series C Follow On investment from
- 4 March 2021
Exscientia completes $100 million Series C financing round with BlackRock funds Proceeds to further accelerate AI drug discovery platform and pipeline OXFORD, 4th March 2021 – Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company’s Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the round totalled $100 million in funding. This new capital will be used to support Exscientia’s platform development towards autonomous drug design. In addition, the company will extend its proprietary pipeline
read morePeptone secures £1.84 million Seed investment led by Hoxton Ventures
- 8 January 2021
Peptone’s protein engineering operating system which speeds up medicine development secures $2.5m investment 8 January 2021, London, UK: In a year that has seen scientists heralded as heroes and the future of protein-based medicine has sat at the coalface of a pandemic, one startup is looking to increase the pharmaceutical industry’s chances of developing future medicines quicker than ever before. Peptone, the computational physics company, has built the world’s first protein engineering operating system and, thanks to $2.5 million seed round led by Hoxton Ventures and supported by dRx Capital, a venture arm of Novartis Pharma AG, Founders Factory and
read moreAflorithmic Labs secures £1 million Seed investment from Crowd Media
- 3 February 2021
Voice Cloning AI Startup Aflorithmic Raises £1M, Making Affordable, Personalized Text-to-Voice Audio A Reality For Marketers and Content Creators London, February 3, 2020, Aflorithmic Labs Ltd, a London/Barcelona based AI Audio-As-A-Service startup, announced today that it has raised a £1 Million Seed Round from Australian media company Crowd Media Holdings (ASX: CM8 & FWB: CM3). Aflorithmic enables fully automated, scalable audio production by using synthetic media, voice cloning and audio mastering, to then deliver it onto any device or platform. With this Audio-As-A-Service, anybody can create beautiful, podcast-quality audio, tailored to each individual listener. Get Deal News in your inbox
read moreLimitless Technology secures £7.3 million Series B investment led by
- 2 February 2021
Limitless Announces $10m Series B, adds Genesys as Investor and Technology Partner UK GigCX platform innovator Limitless continues global expansion and accelerates CX transformation with Genesys Cloud integration and new investment led by Redline Capital February 2, 2021: London, UK - Limitless, the AI-driven gig customer experience platform, today announced it has raised $10 million in financing. The Series B investment is led by Redline Capital and features new investment from Genesys, as well as continued participation from AlbionVC and Unilever Ventures. In addition to its latest funding achievements, Limitless also recently entered into a new technology partnership with Genesys, which was announced today by the global leader in cloud customer and contact
read moreKinomica secures £3.9 million Seed investment led by BGF and
- 17 December 2020
KINOMICA SECURES £3.9M INVESTMENT FOR PIONEERING CELL SIGNALLING TECHNOLOGY TO AID PRECISION MEDICINE DEVELOPMENT The deal cements the business’ ambition to become a world-leader in cell signalling bioinformatics by 2022 Proteomic-data science and diagnostics company, Kinomica, has secured £3.9m in funding for pioneering technology that could prove integral to the development of new drug treatments. KScan™, a next-generation biomarker and molecular diagnostics platform, has been designed to aid the development of kinase inhibitor drugs for treating cancer patients and other conditions. It can be utilised at every stage of the drug development process; from generating novel drug targets, to investigating
read moreHero Wellbeing secures £825k Seed investment from Mercia
- 21 December 2020
Digital wellbeing company set for healthy future as it raises £825k A healthtech platform has raised £825,000 investment from NPIF – Mercia Equity Finance, which is managed by Mercia and part of the Northern Powerhouse Investment Fund, to support its continued growth. The funding will allow hero to further enhance its software platform and develop its marketing strategy. The Leeds-based company helps organisations to deliver tailored health and wellbeing programs and offers services ranging from coaching and training to medical screening and health and nutrition advice. What makes hero unique is its Navigator platform, which can track the impact of different wellbeing
read morenPlan secures £13.43 million Series A investment led by GV
- 23 March 2021
London, UK, 23 March 2021: nPlan, a company that uses machine learning to forecast the duration, risks and opportunities of construction projects, has secured an $18.5 million investment round, led by GV (formerly Google Ventures). The company’s proprietary AI algorithms have analysed nearly $1 trillion worth of global construction projects and deploys this learning to spot delays and recommend improvements with an accuracy and scale previously not possible. In doing so, nPlan’s data-led insights effectively reduce the volatility of and increase investor confidence in construction projects. There continues to be a significant global appetite for major infrastructure projects, both in the
read moreThe Modular Analytics Company secures £400k Seed investment from Instinctive
- 23 February 2021
The Modular Analytics Company Raises $600K in Funding for Innovative and Affordable, Enterprise-ready AI and ML Solutions – Investment Puts Modular Analytics Company on Target for Attaining 2021 Business Goals – MANCHESTER, England – February 23, 2021 – The Modular Analytics Company (TMAC), an artificial intelligence and machine learning solution provider, today announces it raised $600K (£400,000) in its latest round of funding from technology partner Instinctive BI for its innovative and affordable, enterprise-ready AI and ML solutions.TMAC uses analytics and machine-based learning to empower its clients to make better, faster, and valuable decisions. Speed is a critical factor for TMAC and their clients in
read more